These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32187786)

  • 1. Identifying human leukocyte antigen (HLA)-compatible platelets using the Matchmaker programme in alloimmunised platelet-refractory patients.
    Kreuter JD
    Transfus Med; 2020 Feb; 30(1):5-6. PubMed ID: 32187786
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors.
    Vox Sang; 2003 Jan; 84(1):73-88. PubMed ID: 12542737
    [No Abstract]   [Full Text] [Related]  

  • 4. Alloimmunization as a problem for platelet transfusion.
    Bonacossa IA
    Transfus Med Rev; 1990 Apr; 4(2):144-8. PubMed ID: 2134622
    [No Abstract]   [Full Text] [Related]  

  • 5. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
    Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
    Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.
    Jackman RP; Deng X; Bolgiano D; Lebedeva M; Heitman JW; Busch MP; Slichter SJ; Norris PJ
    Blood; 2013 Apr; 121(16):3261-6; quiz 3299. PubMed ID: 23393051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets.
    O'Rafferty C; Rooney G; Hagan R; Woolfson M; O'Donghaile D; Fitzgerald J
    Transfus Med; 2017 Oct; 27 Suppl 5():369-374. PubMed ID: 28393455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do I … manage the platelet transfusion-refractory patient?
    Juskewitch JE; Norgan AP; De Goey SR; Duellman PM; Wakefield LL; Gandhi MJ; Stubbs JR; Kreuter JD
    Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases.
    Pai SC; Lo SC; Lin Tsai SJ; Chang JS; Lin DT; Lin KS; Lin LI
    Transfusion; 2010 Nov; 50(11):2318-27. PubMed ID: 20497513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion.
    Ikeda H; Mitani T; Ohnuma M; Haga H; Ohtzuka S; Kato T; Nakase T; Sekiguchi S
    Vox Sang; 1989; 57(3):213-7. PubMed ID: 2617957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets as immunogens.
    Waters AH
    Vox Sang; 1994; 67 Suppl 3():125-7. PubMed ID: 7975474
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory response to platelet transfusion therapy.
    Eisenberg S
    J Infus Nurs; 2010; 33(2):89-97. PubMed ID: 20228646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of anti-HLA-A1 and anti-PLA1 antibodies on the efficacy of platelet transfusion].
    Forest G
    Union Med Can; 1984 Jul; 113(7):607-9. PubMed ID: 6333099
    [No Abstract]   [Full Text] [Related]  

  • 18. HLA-Mediated Platelet Refractoriness.
    Schmidt AE; Refaai MA; Coppage M
    Am J Clin Pathol; 2019 Mar; 151(4):353-363. PubMed ID: 30285067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet alloantigens--molecular, genetic, and clinical aspects.
    Mueller-Eckhardt C; Santoso S; Kiefel V
    Vox Sang; 1994; 67 Suppl 3():89-93. PubMed ID: 7975519
    [No Abstract]   [Full Text] [Related]  

  • 20. Simple method for differentiating between HLA and platelet-specific antibodies by flow cytometry.
    Freedman J; Hornstein A
    Am J Hematol; 1991 Dec; 38(4):314-20. PubMed ID: 1746540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.